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Abstract
Background: Many migraineurs who seek care in headache clinics are refractory to treatment, despite advances in
headache therapies. Epidemiology is poorly characterized, because diagnostic criteria for refractory migraine were
not available until recently. We aimed to determine the frequency of refractory migraine in patients attended in
the Headache Unit in a tertiary care center, according to recently proposed criteria.
Methods: The study population consisted of a consecutive sample of 370 patients (60.8% females) with a mean
age of 43 years (range 14-86) evaluated for the first time in our headache unit over a one-year period (between
October 2008 and October 2009). We recorded information on clinical features, previous treatments, Migraine
Disability Assessment Score (MIDAS), and final diagnosis.
Results: Overall migraine and tension-type headache were found in 46.4% and 20.5% of patients, respectively.
Refractory migraine was found in 5.1% of patients. In refractory migraineurs, the mean MIDAS score was 96, and
36.8% were medication-overusers.
Conclusions: Refractory migraine is a relatively common and very disabling condition between the patients
attended in a headache unit. The proposed operational criteria may be useful in identifying those patients who
require care in headache units, the selection of candidates for combinations of prophylactic drugs or invasive
treatments such as neurostimulation, but also to facilitate clinical studies in this patient group.
Background
Migraine is a common and disabling primary headache
disorder [1-3]. Despite substantial advances in migraine
therapy [4], many patients are considered refractory to
treatment. Although the term refractory migraine (RM)
has been used in the literature for decades, operational
criteria were not defined until recently [5,6].
The Refractory Headache Special Interest Section of
the American Headache Society proposed the criteria
for both RM and refractory chronic migraine (R-CM)
[6,7]. According to this definition, refractory migraineurs
must meet the International Classification of Headache
Disorders, Second Edition (ICHD-2) criteria for
migraine or chronic migraine [1]. Headaches need to
cause significant interference with function or quality of
life despite modification of triggers, lifestyle factors, and
adequate trials of acute and preventive medicines. The
trials with acute medicines should include both a triptan
and dihydroergotamine (DHE) intranasal or injectable
formulation and either nonsteroidal anti-inflammatory
drugs (NSAID) or combination analgesics. The defini-
tion requires that patients fail adequate trials of preven-
tive medicines with established efficacy, alone or in
combination, from more than 2 of 4 drug classes includ-
ing: beta-blockers, anticonvulsants, tricyclics, and cal-
cium channel blockers. The definition also includes
modifiers for the presence or absence of medication
overuse headache (MOH), and with or without signifi-
cant disability, according to the Migraine Disability
Assessment Score (MIDAS).
The proportion of patients with RM and R-CM
attending headache units seems to be growing [8], but
the actual epidemiology of this disorder is unknown [9].
The purpose of this study was to investigate the
frequency of refractory migraineurs, according to the
proposed criteria for episodic RM and R-CM [6,7]
among the patients who seek care for the first time in a
headache unit.* Correspondence: pirimia@unav.es
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Methods
Study Population
This study was based on a sample of consecutive
patients attended for the first time (only new patients)
in the headache unit based in the Department of Neu-
rology at the University Clinic of Navarra, during a one-
year period (from October 2008 to October 2009).
Patients attended in our headache unit may be referred
from primary care, the emergency department, other
health professionals, or self-referred. All patients under-
went a clinical interview and neurological examination
by the first author. Information on clinical features, pos-
sible triggers, previous or current preventive and abor-
tive treatments and diagnosis were recorded. Additional
investigations to rule out secondary causes of headache
(mainly cerebral magnetic resonance imaging) were per-
formed depending on the results of the clinical history
and neurological examination. MIDAS was used as the
clinical measure of headache-related disability [10].
MIDAS scores can be classified into four severity grades:
little or none (0-5), mild (6-10), moderate (11-20), and
severe (≥ 21). A standardized questionnaire based on
the ICHD-2 was used for new patients attended in the
headache unit. The information obtained from the
patients was stored in a Headache database for statistical
analysis. Each patient or the patient’s guardian gave
their informed consent and the local Ethics Committee
approved the study.
Classification
Headaches were classified according to the diagnostic
criteria of the International Classification of Headache
Disorders, second edition (ICHD-2) [1] and revised cri-
teria for chronic migraine and medication overuse head-
ache (MOH) [11]. To define patients with episodic RM
and R-CM, we used the criteria proposed by Schulman
et al. [6], which were modified during the validation
procedure [7].
Statistics
Statistical analyses were performed using SPSS version
15.0 for Windows (SPSS Inc, Chicago, IL, USA). For
categorical (qualitative) data, the c2 test was used to
check the differences between the two groups. When
the expected frequencies were less than 5, Fisher’s exact
test was performed.
For comparisons of two or more means, the analysis
of variance (ANOVA) was performed. When a signifi-
cant result was obtained in the ANOVA test, a post-hoc
analysis (Scheffé’s test) was carried out to perform
multiple comparisons.
In all cases, statistical significance was defined as p <
0.05.
Results
Patients and diagnoses
During the study period, 370 Caucasian patients (225
females) with headache were attended for the first time
(new patients) in our headache clinic. The mean age
was 43 years (range: 14-86 years). The final diagnoses of
the patients are specified in Table 1. Of the participants,
172 (46.4%) had migraine, 76 (20.5%) tension-type head-
ache, 13 patients (3.5%) had cluster headache or other
trigeminal autonomic cephalalgias and 22 (5.9%) had
other primary headaches. In our group, 70 patients
(18.9%) had secondary headaches and nine (2.4%) other
headache types (including two patients with primary tro-
chlear headache). Forty patients (10, 8%) were diagnosed
as having MOH. The headache most frequently asso-
ciated with MOH was migraine in 27 patients (67.5% of
the cases of MOH). In relation with headache frequency
at admission, 125 patients (33.7%) reported headache
Table 1 Diagnoses according to ICHD-2 and revised
ICHD-2 criteria, given at the Headache Clinic of the
University Clinic of Navarra
Diagnoses n %
Migraine 172 46.4
Migraine without aura 110 29.7
Migraine with aura 42 11.3
Chronic migraine 20 5.4
Tension-type headache (TTH) 76 20.8
Episodic infrequent TTH 5 1.3
Episodic frequent TTH 61 16.4
Chronic TTH 10 2.7
Cluster headache and other trigeminal autonomic
cephalalgias
13 3.5
Cluster headache 12 3.2
Paroxysmal hemicrania 1 0.2
Other primary headaches 22 5.9
Primary stabbing headache 7 1.9
Primary cough headache 1 0.2
Primary exertional headache 2 0.5
Primary thunderclap headache 2 0.5
Hemicrania continua 2 0.5
New daily-persistent headache 8 2.1
Secondary headaches 70 18.9
Medication-overuse headache 40 10.8
Cervicogenic headache 15 4.0
Other secondary headaches 15 4.0
Cranial neuralgias and central causes of facial pain 8 2.1
Trigeminal neuralgia 5 1.3
Occipital neuralgia 3 0.8
Other headache types 9 2.4
Total 370 100
International Classification of Headache Disorders, second edition (ICHD-2); n:
number of patients; %: percentages.
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more than 15 days per month in the previous three
months.
RM and R-CM
19 patients (11 women) fulfilled the diagnostic criteria
for RM or R-CM, representing 5.1% of all patients. The
features of RM or R-CM are summarised in Table 2. Of
the 19 patients, four (one woman) met the criteria for
RM, while 15 patients (10 women) met the criteria for
R-CM. The mean age of refractory migraineurs was 43
years (range, 26-66 years)
All refractory migraineurs had undergone abortive
treatments with triptans and NSAID, except one patient
who was allergic to NSAID. Intranasal or injectable
dihydroergotamine was not used in our patients because
this drug is not available in Spain. All possible triggers
and lifestyle factors were addressed.
All refractory migraineurs had undergone a therapeu-
tic trial with more than 2 groups of preventive drugs for
at least 2 months at optimal or maximal tolerated doses,
unless terminated early due to adverse effects. 17
patients had received tricyclic antidepressants (mainly
amitriptyline, but also nortriptyline), 14 patients had
received beta-blockers (mainly propranolol, but also ate-
nolol and metoprolol), 16 patients had received calcium-
channel-blockers (mainly flunarizine) and 18 patients
had received anticonvulsants (14 topiramate, 10 valpro-
ate, 5 gabapentin, 2 lamotrigine, 1 pregabaline, 1 carba-
mazepine and 1 zonisamide). Three patients experienced
intolerance to preventive drugs (topiramate in 3 and
amitriptyline in 1).
Additionally some patients had received other preven-
tive treatments, with at least one positive randomized
controlled trial in migraine, but not included in the cur-
rent proposed criteria for RM and R-CM [6,7]. These
additional treatments include botulinum toxin infiltra-
tion in 3 patients, pizotifen in 1, and vitamin B2 in 1.
These treatments were not taken into account in estab-
lishing the diagnosis of RM or R-CM. Other common
treatments used in refractory migraineurs to manage
comorbid psychiatric disorders included serotonine
reuptake inhibitors in 7 patients and lithium in 3
patients. Two patients had also received treatment with
occipital nerve blocks.
The mean MIDAS score in refractory migraineurs was
96 (45-180), and therefore, in these cases the diagnosis
of RM and R-CM may be qualified with the modifier
“with significant disability”.
In our headache clinic, 36, 8% of patients with RM or
R-CM overused analgesics and therefore in these cases
the diagnosis of RM and R-CM may be qualified with
the modifier “with medication overuse”.
For comparison purposes, refractory migraineurs were
classified into four groups: RM without MOH, RM with
MOH, R-CM without MOH and R-CM with MOH
(Table 3). No statistical differences between the groups
were found when comparing for sex, age, age of head-
ache onset, preventive drugs and abortive medicines.
Only when comparing the MIDAS scores, differences
between the three groups were statistically significant (F
= 11.37, p = 0.001). Sheffé’s test demonstrated that dif-
ferences in MIDAS scores were significant (p = 0.001)
when comparing the groups of episodic RM with MOH
(mean MIDAS of 65) or RM without MOH (mean
MIDAS of 56) against the group of R-CM with MOH
(mean MIDAS of 131.6). The differences in MIDAS
scores were also significant (p = 0.02) when comparing
the group of R-CM with MOH (mean MIDAS of 131.6)
against the group of R-CM without MOH (mean
MIDAS of 92.5).
Discussion
RM and R-CM accounted for 5.1% of patients attended
for the first time in our headache unit. To our knowl-
edge, this is the first study to describe the frequency of
refractory migraineurs in a headache unit with the cur-
rent diagnostic criteria. The proposed criteria for both
RM and R-CM introduce the new term “refractory” into
the classification of chronic headache [12-14]. The
ICHD-2 diagnostic criteria do not provide any usable
classification for this relatively common condition
between the patients attended in tertiary headache units.
Refractory headache patients are usually referred to spe-
cialized clinics [15] and most of them require follow-up
visits for several months. Headache specialists intuitively
Table 2 RM and R-CM characteristics*
Feature Study group
(n = 19)
Sex
Female 11 (57.9%)
Male 8 (42.1%)
Age, mean (range) 43 (26-66)
Age at headache onset, mean (range) 22.7 (13-36)
Type of migraine
Episodic migraine 4 (21.1%)
Chronic migraine 15 (78.9%)
MIDAS score, mean (range) 96 (45-180)
Medication overuse
Yes 7 (36.8%)
No 12 (63.2%)
*Values are number (percentage) unless otherwise stated
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recognize when a patient is refractory, but with the pro-
posed criteria for both RM and R-CM is possible to
define the frequency of this patient population. The
benefits of the newly proposed diagnostic criteria are
not only the possibility to study the epidemiology of RM
and R-CM, but also to define the treatment strategies
for these challenging patients.
The overall age and sex distribution among headache
patients in our headache unit is similar to previous stu-
dies in other headache units in Spain [16]. In our RM
and R-CM patients, headaches caused a significant inter-
ference with function and quality of life. All our RM and
R-CM patients experienced severe disability (MIDAS ≥
21) and therefore the diagnosis of RM and R-CM may
be qualified with the modifier “with significant disabil-
ity”. The noteworthy MIDAS found in refractory migrai-
neurs is consistent with the scores observed in those
migraneurs treated with neurostimulation after the fail-
ure of several preventive drugs [17], and may be related
to the significant degree of disability caused by refrac-
tory pain. Moreover, chronic migraine is more disabling
than episodic migraine in the population [3], and like-
wise in our sample, the highest MIDAS corresponds to
R-CM. Our study shows that the proportion of patients
with chronic migraine is very similar to the proportion
of RM and R-CM. These findings can be explained
because refractory migraineurs may suffer from episodic
or chronic migraine. Furthermore, in the chronic
migraine revised ICHD-2 criteria [11], medication-over-
use has to be ruled out, and therefore some migraneurs
with near daily headache have to be classified as having
MOH. Between our patients classified as having medica-
tion-overuse headache, most were migraineurs. Accord-
ing to revised ICHD-2 criteria [17], if a patient has
headache on ≥ 15 days/month after > 3 months of regu-
lar overuse of one or more acute/symptomatic treatment
drugs, and the headache has developed or markedly
worsened during medication overuse, then a diagnosis
of MOH can be made. If the headache persists after 2
months of withdrawal, then a new diagnosis of chronic
migraine is given. Considering that definition of RM and
R-CM was to have worldwide application, it was not
considered practical to avoid medication overuse. For
that reason, medication overuse was considered a modi-
fier, although, ideally, medications potentially causing
MOH must be withdrawn before a patient with
migraine can be identified as refractory.
Our study has some evident limitations. The best
approach to estimate the proportion of patients with
RM and R-CM is a population based study and not a
single center study, such as the present one. However,
the information regarding the failure of adequate trials
of acute treatments and preventive drugs (required for
the diagnosis of RM and R-CM) is difficult to obtain by
means of questionnaires or phone surveys, which are
the usual methods in population-based studies. This
sort of information is best obtained in person by an
experienced neurologist with enough time to obtain the
history, and review the clinical records, as occurs in
most of headache units. Also, our data were obtained
from a single headache unit and therefore our findings
may not be representative of other tertiary headache
centres. However, the proportion of patients with
chronic headache and the distribution of diagnoses
observed in the present study are similar to other head-
ache units. In our sample, and also in several series of
patients attended in headache units, patients with
chronic headaches were over-represented [18]. Concern-
ing headache diagnoses, the high frequency of tension-
type headache observed in our population, but also in
previous reports [16,19,20], contrasts with the experi-
ence of other headache units [21,22]. These differences
may be partially explained by the pattern of referral to
the headache unit (some of our patients are self-
referred) and the application of ICHD-II criteria in the
present study. In fact, the distribution of diagnoses in
the present work is similar to headache units in which
patients were classified according to ICHD-2 [16,23].
Recall bias may constitute an additional limitation and
may have affected our results. Patients might have had
problems remembering the preventive therapeutic
groups tried, or whether the trial was adequate, which is
needed for the definition of RM and R-CM. However,
preventive drugs were used during prolonged periods of
time and most of the patients remembered details of the
trials; in the remaining cases, such information was
obtained from medical records.
The reliability and external validity of the proposed
diagnostic criteria for RM need to be established in
future studies. We consider that the present criteria are
Table 3 RM and R-CM subgroups characteristics
RM RM R-CM R-CM
without MOH with MOH without MOH with MOH
n 2 2 10 5
Age, mean (range) 34.5 (24-43) 38 (28-48) 42.3 (31-60) 49.8 (36-66)
MIDAS score, mean (range) 56 (50-62) 65 (50-80) 92.5 (45-105) 131.6 (94-180)
MOH: Medication Overuse Headache; n: number of patients; RM: refractory migraine; R-CM: refractory chronic migraine
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valid and exhaustive, but there are two shortcomings.
First, the use of ergotics, even in oral presentation, in
patients with migraine is not common [24]. In Spain
and other countries, DHE is not available either intrana-
sal or injectable forms. Thus, our patients do not meet
the criterion that a trial with DHE (intranasal or inject-
able formulation) is needed for RM or R-CM diagnosis.
Given that the definitions of RM and R-CM are going
to be used worldwide, and the unavailability intranasal
or injectable DHE in several countries, this criterion
must be reviewed. In addition, MOH is included in the
proposed criteria as a modifier and patients can be clas-
sified as having R-CM with or without MOH. We agree
that diagnoses of RM and R-CM may be made even in
patients who overuse analgesics. However, we would
specify in the criteria that overused medication needs to
be withdrawn for two months on at least one occasion,
before the patient can be classified as refractory.
Conclusion
In conclusion, RM and R-CM are relatively common
conditions among patients evaluated for the first time in
a headache unit. Patients with RM and R-CM are
severely disabled and need to be cared by neurologists
attached to specialized headache clinics. The proposed
operational criteria may be useful not only to identify
those patients who require care in headache units but
also to select the candidates for combinations of pro-
phylactic drugs or invasive treatments, such as neurosti-
mulation, and to facilitate clinical studies in this patient
group.
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